bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.32% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.16M.
Overvalued
The company’s latest PE is -0.17, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 291.72K shares, increasing 2.46% quarter-over-quarter.